Description

The last several years have brought tantalizing bits of information regarding potential new therapies for canine hemangiosarcoma. These include drugs/treatments such as the beta blocker propranolol, yunnan baiyao, polysaccharopeptide (Im'Munity), the targeted toxin eBAT, and the CXCR4 inhibitor losartan, among others. This hour will review basics of canine hemangiosarcoma, discuss the available evidence regarding these novel approaches, and discuss strategies to move these “frontier” therapies forward.